Funder
Science and Technology Commission of Shanghai Municipality
Shanghai Municipal Education Commission
National Nature Science Foundation Grant of China
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference11 articles.
1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e8995–e1032.
2. Gilbert RE. SGLT-2 inhibition in patients with kidney disease. Diabetes Metab. 2014;40(6 suppl 1):S23–7.
3. De Pascalis A, Cianciolo G, Capelli I, Brunori G, La Manna G. SGLT2 inhibitors, sodium and off-target effects: an overview. J Nephrol. 2021;34(3):673–80.
4. Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedi UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT22) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16(3):215–22.
5. Devineni D, Curtin CR, Marbury TC, et al. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther. 2015;37(3):610–28.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献